CSIMarket Company Name, Ticker, Industry, else..


Akebia Therapeutics Inc   (NASDAQ: AKBA)
Other Ticker:  
 

Akebia Therapeutics Inc

AKBA's Fundamental analysis



Looking into Akebia Therapeutics Inc growth rates, revenue grew by 75.84 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 1683

Major Pharmaceutical Preparations industry recorded growth of revenues by 4.49 %

Akebia Therapeutics Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on AKBA's Growth


Akebia Therapeutics Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 8.83 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.41.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.


• More on AKBA's Valuation
 
 Total Debt (Millions $) 47
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 450,998
 Net Income/Employee (TTM) $ -110,520
 Receivable Turnover (TTM) 4.69
 Tangible Book Value (Per Share $) -0.14

Akebia Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 8.83 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.41.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.

Akebia Therapeutics Inc Price to Book Ratio is at 25.65 lower than Industry Avg. of 33.04. and higher than S&P 500 Avg. of 0.01

• More on AKBA's Valuation

•  Market Capitalization (Millions $) 631
•  Shares Outstanding (Millions) 242
•  Employees 410
•  Revenues (TTM) (Millions $) 185
•  Net Income (TTM) (Millions $) -45
•  Cash Flow (TTM) (Millions $) 71
•  Capital Exp. (TTM) (Millions $) 0
•  Total Debt (Millions $) 47
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 450,998
•  Net Income/Employee(TTM) $ -110,520
•  Receivable Turnover Ratio (TTM) 4.69
•  Tangible Book Value (Per Share $) -0.14

•  Market Capitalization (Millions $) 631
•  Shares Outstanding (Millions) 242
•  Employees 410
•  Revenues (TTM) (Millions $) 185
•  Net Income (TTM) (Millions $) -45
•  Cash Flow (TTM) (Millions $) 71
•  Capital Exp. (TTM) (Millions $) 0


    AKBA's Profitability Comparisons
Akebia Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 23.57 %.

Akebia Therapeutics Inc net profit margin of 10.66 % is currently ranking no. 32 in Major Pharmaceutical Preparations industry, ranking no. 73 in Healthcare sector and number 955 in S&P 500.


Profitability by Segment
Total 10.66 %



  Ratio
•   Capital Ratio (MRQ) 2.23
•  Total Debt to Equity (MRQ) 1.89
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.77
•  Inventory Turnover Ratio (TTM) 2.95



Akebia Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 23.57 %.

Akebia Therapeutics Inc net profit margin of 10.66 % is currently ranking no. 32 in Major Pharmaceutical Preparations industry, ranking no. 73 in Healthcare sector and number 955 in S&P 500.

• More on AKBA's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com